ZYMEWORKS INC. Research and Development Expense
ZYMEWORKS INC. (ZYME) reported Research and Development Expense of $32.04 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-02.
Discontinued › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2024-05-02
- ZYMEWORKS INC. research and development expense for the quarter ending 2024-03-31 was $32.04M, a 30.21% decline year-over-year.
- ZYMEWORKS INC. research and development expense for the quarter ending 2023-12-31 was $25.52M, a 51.81% decline year-over-year.
- ZYMEWORKS INC. research and development expense for the quarter ending 2023-09-30 was $32.77M, a 11.65% decline year-over-year.
- ZYMEWORKS INC. research and development expense for the quarter ending 2023-06-30 was $39.41M, a 29.66% decline year-over-year.
- ZYMEWORKS INC. research and development expense for fiscal 2023 was $143.62M, a 31.15% decline from fiscal 2022.
- ZYMEWORKS INC. research and development expense for fiscal 2022 was $208.60M, a 4.43% increase from fiscal 2021.
- ZYMEWORKS INC. research and development expense for fiscal 2021 was $199.75M, a 16.68% increase from fiscal 2020.
- ZYMEWORKS INC. research and development expense for fiscal 2020 was $171.20M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $32.04M 10-Q · filed 2024-05-02 | $57.57M derived: sum of 2 quarters · filed 2024-05-02 | $90.34M derived: sum of 3 quarters · filed 2024-05-02 | $129.75M derived: sum of 4 quarters · filed 2024-05-02 |
| 2023-12-31 | $25.52M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $58.30M derived: sum of 2 quarters · filed 2024-03-06 | $97.71M derived: sum of 3 quarters · filed 2024-03-06 | $143.62M 10-K · filed 2024-03-06 |
| 2023-09-30 | $32.77M 10-Q · filed 2023-11-07 | $72.18M derived: sum of 2 quarters · filed 2023-11-07 | $118.09M 10-Q · filed 2023-11-07 | $171.06M derived: sum of 4 quarters · filed 2024-05-02 |
| 2023-06-30 | $39.41M 10-Q · filed 2023-08-10 | $85.32M 10-Q · filed 2023-08-10 | $138.29M derived: sum of 3 quarters · filed 2024-05-02 | $175.38M derived: sum of 4 quarters · filed 2024-05-02 |
| 2023-03-31 | $45.91M 10-Q · filed 2024-05-02 | $98.88M derived: sum of 2 quarters · filed 2024-05-02 | $135.98M derived: sum of 3 quarters · filed 2024-05-02 | $192.00M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $52.97M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $90.06M derived: sum of 2 quarters · filed 2024-03-06 | $146.09M derived: sum of 3 quarters · filed 2024-03-06 | $208.60M 10-K · filed 2024-03-06 |
| 2022-09-30 | $37.10M 10-Q · filed 2023-11-07 | $93.12M derived: sum of 2 quarters · filed 2023-11-07 | $155.63M 10-Q · filed 2023-11-07 | $210.49M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | $56.02M 10-Q · filed 2023-08-10 | $118.53M 10-Q · filed 2023-08-10 | $173.40M derived: sum of 3 quarters · filed 2024-03-06 | $223.29M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | $62.51M 10-Q · filed 2023-05-08 | $117.38M derived: sum of 2 quarters · filed 2024-03-06 | $167.27M derived: sum of 3 quarters · filed 2024-03-06 | |
| 2021-12-31 | $54.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $104.76M derived: sum of 2 quarters · filed 2024-03-06 | $199.75M 10-K · filed 2024-03-06 | |
| 2021-09-30 | $49.89M 10-Q · filed 2022-11-08 | $144.89M 10-Q · filed 2022-11-08 | ||
| 2020-12-31 | $171.20M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |